Comparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related Tolerability.
To describe patient preferences in selecting specific biologics and compare clinical response using patient reported outcomes (PROs) among patients with rheumatoid arthritis (RA) started on different anti-tumor necrosis factor (TNF) therapies.Participants were enrollees in Kaiser Permanente Northern...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4805235?pdf=render |
| _version_ | 1818494537148923904 |
|---|---|
| author | Iris Navarro-Millán Lisa J Herrinton Lang Chen Leslie Harrold Liyan Liu Jeffrey R Curtis |
| author_facet | Iris Navarro-Millán Lisa J Herrinton Lang Chen Leslie Harrold Liyan Liu Jeffrey R Curtis |
| author_sort | Iris Navarro-Millán |
| collection | DOAJ |
| description | To describe patient preferences in selecting specific biologics and compare clinical response using patient reported outcomes (PROs) among patients with rheumatoid arthritis (RA) started on different anti-tumor necrosis factor (TNF) therapies.Participants were enrollees in Kaiser Permanente Northern California. Patients with RA who had at least two provider visits and started a new anti-TNF therapy from 10/2010-8/2011, were eligible for participation in this longitudinal study. Using a telephone survey, patient preferences in biologic selection and RAPID3, MDHAQ, and SF-12 scores were collected at baseline and at 6 months. Patient scores rating injection/infusion-site burning and stinging (ISBS) were collected at 6 months.In all, 267 patients with RA responded to the baseline survey, of whom 57% preferred an injectable biologic, 22% preferred an infused biologic, and 21% had no preference. Motivation for injectable biologics was convenience (92%) and for infusion therapy was dislike or lack of self-efficacy for self-injection (16%). After 6 months of treatment with anti-TNF, 70% of the 177 patients who answered the ISBS question reported ISBS with the last dose; on a scale of 1 (none) to 10 (worst), 41% of these reported a score of 2-5; and 29% reported a score of 6-10. Adalimumab users experienced 3.2 times (95% confidence interval 1.2-8.6) the level of ISBS that etanercept users experienced. There were no significant differences in RAPID3, MDHAQ, or SF-12 scores between etanercept or adalimumab initiators.Convenience and fear of self-injection were important considerations to patients selecting a biologic drug. Although more convenient, adalimumab associated with more ISBS than did etanercept, and this rate was higher than reported in clinical trials. At 6 months, PROs did not differ between etanercept and adalimumab users. |
| first_indexed | 2024-12-10T18:07:51Z |
| format | Article |
| id | doaj.art-0c0e0d42087a43739962ebd9d063bea7 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-10T18:07:51Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-0c0e0d42087a43739962ebd9d063bea72022-12-22T01:38:34ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01113e014978110.1371/journal.pone.0149781Comparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related Tolerability.Iris Navarro-MillánLisa J HerrintonLang ChenLeslie HarroldLiyan LiuJeffrey R CurtisTo describe patient preferences in selecting specific biologics and compare clinical response using patient reported outcomes (PROs) among patients with rheumatoid arthritis (RA) started on different anti-tumor necrosis factor (TNF) therapies.Participants were enrollees in Kaiser Permanente Northern California. Patients with RA who had at least two provider visits and started a new anti-TNF therapy from 10/2010-8/2011, were eligible for participation in this longitudinal study. Using a telephone survey, patient preferences in biologic selection and RAPID3, MDHAQ, and SF-12 scores were collected at baseline and at 6 months. Patient scores rating injection/infusion-site burning and stinging (ISBS) were collected at 6 months.In all, 267 patients with RA responded to the baseline survey, of whom 57% preferred an injectable biologic, 22% preferred an infused biologic, and 21% had no preference. Motivation for injectable biologics was convenience (92%) and for infusion therapy was dislike or lack of self-efficacy for self-injection (16%). After 6 months of treatment with anti-TNF, 70% of the 177 patients who answered the ISBS question reported ISBS with the last dose; on a scale of 1 (none) to 10 (worst), 41% of these reported a score of 2-5; and 29% reported a score of 6-10. Adalimumab users experienced 3.2 times (95% confidence interval 1.2-8.6) the level of ISBS that etanercept users experienced. There were no significant differences in RAPID3, MDHAQ, or SF-12 scores between etanercept or adalimumab initiators.Convenience and fear of self-injection were important considerations to patients selecting a biologic drug. Although more convenient, adalimumab associated with more ISBS than did etanercept, and this rate was higher than reported in clinical trials. At 6 months, PROs did not differ between etanercept and adalimumab users.http://europepmc.org/articles/PMC4805235?pdf=render |
| spellingShingle | Iris Navarro-Millán Lisa J Herrinton Lang Chen Leslie Harrold Liyan Liu Jeffrey R Curtis Comparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related Tolerability. PLoS ONE |
| title | Comparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related Tolerability. |
| title_full | Comparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related Tolerability. |
| title_fullStr | Comparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related Tolerability. |
| title_full_unstemmed | Comparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related Tolerability. |
| title_short | Comparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related Tolerability. |
| title_sort | comparative effectiveness of etanercept and adalimumab in patient reported outcomes and injection related tolerability |
| url | http://europepmc.org/articles/PMC4805235?pdf=render |
| work_keys_str_mv | AT irisnavarromillan comparativeeffectivenessofetanerceptandadalimumabinpatientreportedoutcomesandinjectionrelatedtolerability AT lisajherrinton comparativeeffectivenessofetanerceptandadalimumabinpatientreportedoutcomesandinjectionrelatedtolerability AT langchen comparativeeffectivenessofetanerceptandadalimumabinpatientreportedoutcomesandinjectionrelatedtolerability AT leslieharrold comparativeeffectivenessofetanerceptandadalimumabinpatientreportedoutcomesandinjectionrelatedtolerability AT liyanliu comparativeeffectivenessofetanerceptandadalimumabinpatientreportedoutcomesandinjectionrelatedtolerability AT jeffreyrcurtis comparativeeffectivenessofetanerceptandadalimumabinpatientreportedoutcomesandinjectionrelatedtolerability |